{"filing":{"accession_number":"0001437749-26-024758","cik":"0001625101","ticker":"PLSE","company_name":"PULSE BIOSCIENCES, INC.","form":"8-K","filing_date":"2026-07-29","report_date":"2026-07-29","primary_document":"plse20260728_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1625101/000143774926024758/plse20260728_8k.htm"},"events":[{"id":21478,"run_id":19374,"accession_number":"0001437749-26-024758","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"The disclosure announces a clinical trial milestone—surpassing the enrollment midpoint of the NANOPULSE-AF pivotal IDE study for the nPulse Cardiac Catheter System. This is a material operational/strategic event for a medical device company, as it signals progress toward regulatory approval and commercialization of a key product candidate. The event does not fit the specific categories of earnings release, M\u0026A, restatement, auditor change, going concern, impairment, shareholder vote, delisting, bankruptcy, covenant breach, cybersecurity incident, dilutive issuance, litigation, debt issuance, dividend, or workforce reduction; it is a clinical development milestone that would affect a reasonable investor's assessment of the company's pipeline progress and near-term regulatory prospects.","company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","filing_date":"2026-07-29","form":"8-K","submitted_at":null,"items":[{"id":21130,"accession_number":"0001437749-26-024758","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The disclosure announces a clinical trial milestone—surpassing the enrollment midpoint of the NANOPULSE-AF pivotal IDE study for the nPulse Cardiac Catheter System. This is a material operational/strategic event for a medical device company, as it signals progress toward regulatory approval and commercialization of a key product candidate. The event does not fit the specific categories of earnings release, M\u0026A, restatement, auditor change, going concern, impairment, shareholder vote, delisting, bankruptcy, covenant breach, cybersecurity incident, dilutive issuance, litigation, debt issuance, dividend, or workforce reduction; it is a clinical development milestone that would affect a reasonable investor's assessment of the company's pipeline progress and near-term regulatory prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T13:02:43.182252+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21130,"accession_number":"0001437749-26-024758","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The disclosure announces a clinical trial milestone—surpassing the enrollment midpoint of the NANOPULSE-AF pivotal IDE study for the nPulse Cardiac Catheter System. This is a material operational/strategic event for a medical device company, as it signals progress toward regulatory approval and commercialization of a key product candidate. The event does not fit the specific categories of earnings release, M\u0026A, restatement, auditor change, going concern, impairment, shareholder vote, delisting, bankruptcy, covenant breach, cybersecurity incident, dilutive issuance, litigation, debt issuance, dividend, or workforce reduction; it is a clinical development milestone that would affect a reasonable investor's assessment of the company's pipeline progress and near-term regulatory prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T13:02:43.182252+00:00","company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","filing_date":"2026-07-29"}]}